BIOGEN IDEC - Investing for Long-Term
Biogen Idec (BIIB) promises to enrich its revenue stream and MS franchise in 2012 with the launch of oral BG-12 (Dimethyl fumerate, R). Clinical news flow from rFactorVIII (PhIII, hemophilia A) and rFactorIX (PhIII, hemophilia B) will make its presence felt in the Hemophilia market while success of Dexpramipexole (PhIII) in Amyotrophic Lateral Sclerosis (ALS) could fill in a significant unmet need! With the updated Tysabri’s (L, natalizumab, RRMS; PhIII in SPMS) label including screening for JCV, approval of Avonex PEN, and additional launches of FAMPRYA (L, RRMS); BIIB expects growth in single-digit for 2012. For more detail, please read our report released on 8th Feb., 2012 on Biogen Idec titled “Investing for Long-Term”.
COMPANIES MENTIONED
BIOGEN IDEC
BIOGEN IDEC
More Publications
CELGENE - Core Business + Pipeline Investments = Long Term Growth
US$ 140.00
February 2012
9 pages
Biogen Idec business profile (company report)
US$ 99.00
August 2011
30 pages
